BrainGate is a long-running academic research collaboration developing implanted brain-computer interfaces for people with paralysis. It is a consortium rather than a company, drawing on researchers at Brown University, Massachusetts General Hospital, Stanford, the Department of Veterans Affairs, and other institutions, and it began the first of its multicenter clinical trials in 2004.
The group’s core technology is an intracortical microelectrode array - a tiny grid of electrodes implanted in the motor or speech cortex - paired with machine-learning decoders that translate the recorded neural activity into intended actions. Over two decades, BrainGate participants with spinal cord injury, ALS, and brainstem stroke have used the system to move computer cursors, control robotic arms, and operate tablets directly from brain signals.
In more recent years the consortium has been central to the breakthroughs in speech BCIs. A 2021 study demonstrated typing by imagined handwriting decoded from the cortex, and a 2023 Nature paper reported a speech neuroprosthesis decoding attempted speech at tens of words per minute, part of the same wave of results that included the UCSF avatar work.
BrainGate’s significance is as the patient, peer-reviewed academic backbone of the field. Where newer commercial entrants such as Neuralink and Synchron draw headlines, much of the foundational evidence that implanted cortical interfaces can safely and usefully restore function to paralyzed people came from BrainGate’s long sequence of trials.